Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis

Annals of Thoracic Surgery

Volumn 102, Issue 6, 2016, Pages 1905-1910

  Iwata, Takekazu ^a   Yoshida, Shigetoshi ^a   Fujiwara, Taiki ^a   Wada, Hironobu ^a   Nakajima, Takahiro ^a   Suzuki, Hidemi ^a   Yoshino, Ichiro ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PIRFENIDONE; PYRIDONE DERIVATIVE;

ADULT; ADVERSE EFFECTS; AGED; COMPLICATION; DISEASE COURSE; DRUG ADMINISTRATION; DRUG SCREENING; FEMALE; HUMAN; IDIOPATHIC PULMONARY FIBROSIS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; LUNG RESECTION; MALE; MIDDLE AGED; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATIONS; PROCEDURES; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SMOKING; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PERIOPERATIVE CARE; PNEUMONECTOMY; POSTOPERATIVE COMPLICATIONS; PYRIDONES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SMOKING;

EID: 84995921796     PISSN: 00034975     EISSN: 15526259     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2016.05.094     Document Type: Article

References (29)

1. 1 Omori, T., Tajiri, M., Baba, T., et al. Pulmonary resection for lung cancer in patients with idiopathic interstitial pneumonia. Ann Thorac Surg 100 (2015), 954–960.
2. 2 Saito, Y., Kawai, Y., Takahashi, N., et al. Survival after surgery for pathologic stage IA non-small cell lung cancer associated with idiopathic pulmonary fibrosis. Ann Thorac Surg 92 (2011), 1812–1817.
3. 3 Yuksel, M., Ozyurtkan, M.O., Bostanci, K., Ahiskali, R., Kodalli, N., Acute exacerbation of interstitial fibrosis after pulmonary resection. Ann Thorac Surg 82 (2006), 336–338.
4. 4 Fujimoto, T., Okazaki, T., Matsukura, T., et al. Operation for lung cancer in patients with idiopathic pulmonary fibrosis: surgical contraindication?. Ann Thorac Surg 76 (2003), 1674–1678 discussion 1679.
5. 5 Sugiura, H., Takeda, A., Hoshi, T., et al. Acute exacerbation of usual interstitial pneumonia after resection of lung cancer. Ann Thorac Surg 93 (2012), 937–943.
6. 6 Suzuki, H., Sekine, Y., Yoshida, S., et al. Risk of acute exacerbation of interstitial pneumonia after pulmonary resection for lung cancer in patients with idiopathic pulmonary fibrosis based on preoperative high-resolution computed tomography. Surg Today 41 (2011), 914–921.
7. 7 Shintani, Y., Ohta, M., Iwasaki, T., et al. Predictive factors for postoperative acute exacerbation of interstitial pneumonia combined with lung cancer. Gen Thorac Cardiovasc Surg 58 (2010), 182–185.
8. 8 Mizuno, Y., Iwata, H., Shirahashi, K., et al. The importance of intraoperative fluid balance for the prevention of postoperative acute exacerbation of idiopathic pulmonary fibrosis after pulmonary resection for primary lung cancer. Eur J Cardiothorac Surg 41 (2012), e161–e165.
9. 9 Sato, T., Teramukai, S., Kondo, H., et al. Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg 147 (2014), 1604–1611.e3.
10. 10 Sato, T., Kondo, H., Watanabe, A., et al. A simple risk scoring system for predicting acute exacerbation of interstitial pneumonia after pulmonary resection in lung cancer patients. Gen Thorac Cardiovasc Surg 63 (2015), 164–172.
11. 11 Watanabe, A., Miyajima, M., Mishina, T., et al. Surgical treatment for primary lung cancer combined with idiopathic pulmonary fibrosis. Gen Thorac Cardiovasc Surg 61 (2013), 254–261.
12. 12 King, T.E. Jr., Bradford, W.Z., Castro-Bernardini, S., et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370 (2014), 2083–2092.
13. 13 Noble, P.W., Albera, C., Bradford, W.Z., et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377 (2011), 1760–1769.
14. 14 Azuma, A., Nukiwa, T., Tsuboi, E., et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171 (2005), 1040–1047.
15. 15 Taniguchi, H., Ebina, M., Kondoh, Y., et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35 (2010), 821–829.
16. 16 Iwata, T., Yoshida, S., Nagato, K., et al. Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis. Surg Today 45 (2015), 1263–1270.
17. 17 Iwata, T., Yoshino, I., Yoshida, S., et al. Effect of perioperative pirfenidone treatment in lung cancer patients with idiopathic pulmonary fibrosis (West Japan Oncology Group 6711L): a phase II study. [abstract] Chest, 148, 2015, 395A.
18. 18 Raghu, G., Collard, H.R., Egan, J.J., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183 (2011), 788–824.
19. 19 Japanese Respiratory Society. Idiopathic Interstitial Pneumonias: Diagnosis and Treatment. 2nd ed., 2011, Nankodo, Tokyo, 67–73.
20. 20 Collard, H.R., Moore, B.B., Flaherty, K.R., et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 176 (2007), 636–643.
21. 21 Kanda, Y., Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48 (2013), 452–458.
22. 22 Masuda, M., Kuwano, H., Okumura, M., et al. Thoracic and cardiovascular surgery in Japan during 2013: Annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 63 (2015), 670–701.
23. 23 Hyzy, R., Huang, S., Myers, J., Flaherty, K., Martinez, F., Acute exacerbation of idiopathic pulmonary fibrosis. Chest 132 (2007), 1652–1658.
24. 24 Kumar, P., Goldstraw, P., Yamada, K., et al. Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection. J Thorac Cardiovasc Surg 125 (2003), 1321–1327.
25. 25 Yoshimura K, Miyamoto A, Uruga H, Morokawa N, Beika Y, Kishi K. A nation-wide survey on prophylaxis for acute exacerbation of idiopathic pulmonary fibrosis following lung surgery for associated lung cancer. The Annual Report by Study Group of Ministry of Health and Welfare for Diffuse Lung Disease. Diffuse Lung Diseases Research Group from the Ministry of Health, Labour and Welfare of Japanese Government 2008. 2009;77–81.
26. 26 Yano, M., Sasaki, H., Moriyama, S., et al. Post-operative acute exacerbation of pulmonary fibrosis in lung cancer patients undergoing lung resection. Interact Cardiovasc Thorac Surg 14 (2012), 146–150.
27. 27 Iyer, S.N., Gurujeyalakshmi, G., Giri, S.N., Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 291 (1999), 367–373.
28. 28 Sato, T., Watanabe, A., Kondo, H., et al. Long-term results and predictors of survival after surgical resection of patients with lung cancer and interstitial lung diseases. J Thorac Cardiovasc Surg 149 (2015), 64–69 70.e1–2.
29. 29 Chiyo, M., Sekine, Y., Iwata, T., et al. Impact of interstitial lung disease on surgical morbidity and mortality for lung cancer: analyses of short-term and long-term outcomes. J Thorac Cardiovasc Surg 126 (2003), 1141–1146.